Immunomodulatory therapy that blocks the suppressive signals of checkpoint proteins (checkpoint blockade), or selectively targets immunosuppressive cells in the tumor microenvironment (such as Tregs), allows for activation and proliferation of tumor-specific T cells, which are able to identify and eliminate cancer cells. The gene discussed is PROS1; the disease is neoplasm.